地舒单抗对比唑来膦酸治疗前列腺癌骨转移

Denosumab versus Zoledronic Acid in the Treatment of Bone Metastases in Prostate Cancer

摘要: 目的：分析地舒单抗对比唑来膦酸治疗前列腺癌骨转移的临床疗效以及不良反应。方法：收集2020年8月至2022年1月期间，在青岛大学附属中心医院、青岛大学附属医院、青岛市立医院治疗的前列腺癌骨转移患者病历资料，按治疗药物分为地舒单抗组和唑来膦酸组，对两组患者治疗前及治疗12周后的骨痛加剧次数、骨痛加重时间、中重度骨痛出现时间、血清碱性磷酸酶(ALP)、不良反应进行评估分析。结果：经两组药物治疗12周后，地舒单抗组的骨痛加剧次数、血清ALP水平明显小于唑来膦酸组。地舒单抗组较唑来膦酸组延缓中重度骨痛发生1.6月，延缓骨痛加重时间3.3个月。两组治疗相关不良反应多为1~2级，安全性整体可控。结论：地舒单抗较唑来膦酸在治疗前列腺癌骨转移可取得更好的临床疗效，安全性整体可控。

Abstract: Objective: To analyze the clinical efficacy and adverse reactions of denosumab and zoledronic acid in the treatment of prostate cancer with bone metastases. Method: The medical records of prostate cancer patients with bone metastasis treated in the Affiliated Central Hospital of Qingdao University, the Affiliated Hospital of Qingdao University and Qingdao Municipal Hospital from August 2020 to January 2022 were collected. According to the treatment drugs, the patients were divided into denosumab group and zoledronic acid group. The aggravation times of bone pain, aggravation time of bone pain, occurrence time of moderate and severe bone pain, serum alkaline phosphatase (ALP) and adverse reactions of the two groups were evaluated before treatment and 12 weeks after treatment. Results: After 12 weeks of drug treatment in both groups, the frequency of bone pain intensification and serum ALP level in the disulzumab group were significantly lower than those in the zoledronic acid group. Compared with zoledronic acid group, the occurrence of moderate and severe bone pain was delayed for 1.6 months and the aggravation time of bone pain was delayed for 3.3 months in the disulzumab group. Most of the treatment-related adverse reactions in the two groups were grade 1~2, with overall controllable safety. Conclusions: Denosumab has better clinical efficacy than zoledronic acid in the treatment of bone metastasis of prostate cancer, and the safety is controllable overall.